We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The CDSCO has approved TLC's new drug application (NDA) of Amphotericin B Liposome for Injection 50 mg in India for immediate importation per approved usage and indication.
Under the terms of the agreement, TLC is eligible to receive up to US$25 million in upfront payments for each product and subsequent regulatory and sales milestone payments.